Although it is hard for many people to imagine, there are defective medical devices being distributed that can lead to serious injury or even death. For this reason, it is important for all people to become familiar with any procedure they are undergoing.
Even if you are one of our Los Angeles readers and you don't know the first thing about Boston Scientific, it is important to stay current with recent defective medical device lawsuits and settlements. You never know when this is something that could impact you or a loved one.
Boston Scientific recently settled a case with the U.S. Department of Justice Department regarding faulty defibrillators. The $30 million settlement should put an end to the case involving the sale of defective defibrillators between the years of 2002 and 2005.
The subsidiaries involved in this case were Cardiac Pacemakers, Guidant and Guidant Sales. The effective devices were sold before Boston Scientific took over these companies; however, they are still on the hook for the trouble that ensued.
Boston Scientific realizes that this is a serious issue and issued a statement discussing the recent settlement. It said, "While the company continues to deny the allegations made in the complaint, it felt it was in the best interests of all parties to settle this matter and avoid further protracted litigation."
There is no denying the fact that these faulty devices needed to be recalled, especially when you consider the fact that the Boston Scientific website states that nine deaths have been attributed to the Renewal devices. Along with this, five deaths have been connected with the Prizm devices.
It is good to know that there are new medical devices being approved to improve the health of those in need. However, cases in which there are defective medical devices can lead to major health concerns and even death. This is why it is important for every patient to have a solid grasp of the procedure they are dealing with.
StarTribune, "Boston Scientific to pay $30 million in defective devices case" James Walsh, Oct. 17, 2013